{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:39:11Z","timestamp":1768556351291,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["61000010"],"award-info":[{"award-number":["61000010"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Augurex Life Sciences Corp"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-0975-4","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T20:33:18Z","timestamp":1459456398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A prospective cohort study of 14-3-3\u03b7 in ACPA and\/or RF-positive patients with arthralgia"],"prefix":"10.1186","volume":"18","author":[{"given":"Marian H.","family":"van Beers-Tas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirkjan","family":"van Schaardenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"issue":"12","key":"975_CR1","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/annrheumdis-2012-202127","volume":"72","author":"LA Stadt van de","year":"2013","unstructured":"van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013;72(12):1920\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"975_CR2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.37830","volume":"65","author":"J Shi","year":"2013","unstructured":"Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013;65(4):911\u20135.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"975_CR3","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.27570","volume":"62","author":"JR Kolfenbach","year":"2010","unstructured":"Kolfenbach JR, Deane KD, Derber LA, O'Donnell CI, Gilliland WR, Edison JD, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"975_CR4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","volume":"72","author":"J Lubbers","year":"2013","unstructured":"Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72(5):776\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"975_CR5","first-page":"S358","volume":"63","author":"WP Maksymowych","year":"2011","unstructured":"Maksymowych WP, Landewe R, van der Heijde D. Serum 14-3-3\u03b7: a rheumatoid arthritis biomarker. Arthritis Rheum. 2011;63(10):S358.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"975_CR6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3899\/jrheum.131446","volume":"41","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, et al. Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41(11):2104\u201313.","journal-title":"J Rheumatol"},{"issue":"9","key":"975_CR7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/15216540500252666","volume":"57","author":"GP Heusden van","year":"2005","unstructured":"van Heusden GP. 14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life. 2005;57(9):623\u20139.","journal-title":"IUBMB Life"},{"issue":"2","key":"975_CR8","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar4547","volume":"16","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, van der Heijde D, Allaart CF, Landewe R, Boire G, Tak PP, et al. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16(2):R99.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"975_CR9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69(3):571\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"975_CR10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380\u20136.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"975_CR11","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT. Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"975_CR12","unstructured":"Hitchon CA, Smolik I, Meng X, Robinson D, El-Gabalawy HS. Serum 14-3-3eta are elevated in indigenous North Americans with rheumatoid arthritis and may predict imminent synovitis in their in at-risk first degree relatives. Arthritis Rheum. 2015;67(10). http:\/\/acrabstracts.org\/abstract\/serum-14-3-3eta-are-elevated-in-indigenous-north-americans-with-rheumatoid-arthritis-and-may-predict-imminent-synovitis-in-their-at-risk-first-degree-relatives\/ . Accessed 1th Dec 2015."},{"key":"975_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","volume":"13","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Med. 2015;13:1.","journal-title":"BMC Med."},{"issue":"8","key":"975_CR14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3899\/jrheum.090346","volume":"36","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol. 2009;36(8):1785\u201391.","journal-title":"J Rheumatol"},{"issue":"7","key":"975_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.22513","volume":"67","author":"A Baillet","year":"2015","unstructured":"Baillet A, Gossec L, Paternotte S, Etcheto A, Combe B, Meyer O, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res. 2015;67(7):905\u201312.","journal-title":"Arthritis Care Res"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-0975-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T05:47:40Z","timestamp":1498283260000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-0975-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-0975-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]},"article-number":"76"}}